Cargando…

Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine

Two doses of Pfizer/BioNTech BNT162b2 mRNA vaccine elicit robust severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing antibodies with frequent adverse events. Here, by applying a high-dimensional immune profiling on 92 vaccinees, we identify six vaccine-induced immune dynamics t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takano, Tomohiro, Morikawa, Miwa, Adachi, Yu, Kabasawa, Kiyomi, Sax, Nicolas, Moriyama, Saya, Sun, Lin, Isogawa, Masanori, Nishiyama, Ayae, Onodera, Taishi, Terahara, Kazutaka, Tonouchi, Keisuke, Nishimura, Masashi, Tomii, Kentaro, Yamashita, Kazuo, Matsumura, Takayuki, Shinkai, Masaharu, Takahashi, Yoshimasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023335/ https://www.ncbi.nlm.nih.gov/pubmed/35545084 http://dx.doi.org/10.1016/j.xcrm.2022.100631

Ejemplares similares

SARS-CoV-2-specific CD4(+) T cell longevity correlates with Th17-like phenotype
por: Terahara, Kazutaka, et al.
Publicado: (2022)

Heterologous SARS-CoV-2 spike protein booster elicits durable and broad antibody responses against the receptor-binding domain
por: Takano, Tomohiro, et al.
Publicado: (2023)

SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine
por: Kotaki, Ryutaro, et al.
Publicado: (2022)

CD62L expression marks SARS-CoV-2 memory B cell subset with preference for neutralizing epitopes
por: Onodera, Taishi, et al.
Publicado: (2023)

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants
por: Moriyama, Saya, et al.
Publicado: (2021)

Longitudinal Analysis of Neutralizing Potency against SARS-CoV-2 in the Recovered Patients after Treatment with or without Favipiravir
por: Shinada, Kanako, et al.
Publicado: (2022)

Glycan engineering of the SARS-CoV-2 receptor-binding domain elicits cross-neutralizing antibodies for SARS-related viruses
por: Shinnakasu, Ryo, et al.
Publicado: (2021)

Structural basis for cross-group recognition of an influenza virus hemagglutinin antibody that targets postfusion stabilized epitope
por: Tonouchi, Keisuke, et al.
Publicado: (2023)

Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants
por: Moriyama, Saya, et al.
Publicado: (2023)

An anti-perfringolysin O monoclonal antibody cross-reactive with streptolysin O protects against streptococcal toxic shock syndrome
por: Matsumura, Takayuki, et al.
Publicado: (2020)

Saliva as a useful tool for evaluating upper mucosal antibody response to influenza
por: Tsunetsugu-Yokota, Yasuko, et al.
Publicado: (2022)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

A case of reinfection with a different variant of SARS-CoV-2: case report
por: Shimada, Nagashige, et al.
Publicado: (2023)

Humoral immunity for durable control of SARS-CoV-2 and its variants
por: Kotaki, Ryutaro, et al.
Publicado: (2023)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

High Fever, Wide Distribution of Viral Pneumonia, and Pleural Effusion are More Critical Findings at the First Visit in Predicting the Prognosis of COVID-19: A Single Center, retrospective, Propensity Score-Matched Case–Control Study
por: Shinoda, Masahiro, et al.
Publicado: (2023)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Editorial: Non-reactogenic vaccines against Q-fever
por: Gregory, Anthony E., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

A CCR5(+) memory subset within HIV-1-infected primary resting CD4(+) T cells is permissive for replication-competent, latently infected viruses in vitro
por: Terahara, Kazutaka, et al.
Publicado: (2019)

Correction to: A CCR5(+) memory subset within HIV-1-infected primary resting CD4(+) T cells is permissive for replication-competent, latently infected viruses in vitro
por: Terahara, Kazutaka, et al.
Publicado: (2019)

Distinct germinal center selection at local sites shapes memory B cell response to viral escape
por: Adachi, Yu, et al.
Publicado: (2015)

High-throughput isolation of SARS-CoV-2 nucleocapsid antibodies for improved antigen detection
por: Fujisawa, Mizuki, et al.
Publicado: (2023)

Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients
por: Lu, Xiuyuan, et al.
Publicado: (2021)

Clinical Features of 154 COVID-19 Patients and the Parameters for the Effective Detection of Pneumonia at the Time of the Initial Diagnosis in Japan
por: Morikawa, Miwa, et al.
Publicado: (2020)

Receptor Usage and the Pathogenesis in Acute and Chronic Virus Infections
por: Tsunetsugu-Yokota, Yasuko, et al.
Publicado: (2012)

Standardized guinea pig model for Q fever vaccine reactogenicity
por: Baeten, Laurie A., et al.
Publicado: (2018)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review
por: Das, Swarnali, et al.
Publicado: (2022)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians
por: Majumder, Md. Anwarul Azim, et al.
Publicado: (2022)

Safety and reactogenicity of second booster doses for mRNA vaccines
por: Wilder-Smith, Annelies, et al.
Publicado: (2023)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
por: Chayachinda, Chenchit, et al.
Publicado: (2023)

Knife’s edge: Balancing immunogenicity and reactogenicity in mRNA vaccines
por: Lee, Jisun, et al.
Publicado: (2023)

Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan
por: Terahara, Kazutaka, et al.
Publicado: (2022)

A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site
por: Onodera, Taishi, et al.
Publicado: (2021)

Assessment of Fcγ receptor-dependent binding of influenza hemagglutinin vaccine-induced antibodies in a non-human primate model
por: Masuta, Yuji, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qdk8vrvl87ii59a9bcvjp8l45n